Promising preliminary efficacy supports the combination of ivosidenib or enasidenib with intensive chemotherapy (Table 1) in newly diagnosed AML, with composite CR rates (CR + CRi + CRp) of 77% in the ivosidenib group and 74% in the enasidenib group; mutation clearance was also observed in 39% and 23% patients with the IDH1 and IDH2 mutations, respectively [33]. This evidence concerns the gene IDH2 and acute myeloid leukemia.